about
Association between the Severity of Influenza A(H7N9) Virus Infections and Length of the Incubation Period.Estimating the Distribution of the Incubation Periods of Human Avian Influenza A(H7N9) Virus Infections.Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple TherapyAssociation between Severity of MERS-CoV Infection and Incubation Period.Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection.Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi ArabiaDirect-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases.Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.Replication and heritability of prostate cancer risk variants: impact of population-specific factors.Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.Incidence and Risk Factors of Coagulation Profile Derangement After Liver Surgery: Implications for the Use of Epidural Analgesia-A Retrospective Cohort Study.Evaluation of animal-to-human and human-to-human transmission of influenza A (H7N9) virus in China, 2013-15.Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.Epidemiology and Elimination of HCV-Related Liver DiseaseRibavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological MonitoringEffectiveness of Live Poultry Market Interventions on Human Infection with Avian Influenza A(H7N9) Virus, China
P50
Q35925898-83846776-8F2F-4162-B429-323A3F689419Q36135777-49C04372-CCC8-4C17-BDF9-32A4E2198CEEQ36180241-2022F19B-9FEC-4128-A396-45D34AF859EEQ36617013-D118FAB1-8090-46C5-964A-0E4CC2D6594BQ36957566-9055A7D6-2DA8-47C0-8793-30B8CD8B5347Q37360113-853A12BF-44E1-44FA-8AF7-A82DE2A203AAQ38830251-88B63E2E-BBA3-4ABF-A72B-023C003E71FEQ38986475-37B716CC-D4D0-4A84-9A40-F1022174FCEBQ39516333-F5FBBF9B-2723-47BD-88C1-69D2B233922CQ41299641-F3AA928E-4BE3-4581-A429-9F72BDC0464FQ41513198-564C71DE-B1A9-412C-882C-442430CDCBB1Q45966725-4DD8C3AD-4DB7-480B-AF94-37165C7CA289Q47111919-495DDCC5-2EE1-44C4-AC49-6497C0040727Q47251318-346254E7-B5B3-4163-B240-859F47CB4007Q47555442-F7C91CCD-FEC7-4414-A207-7EAC86531A85Q54253965-9FE6A3C5-6518-461A-927E-122CB920E2C1Q57297223-491836B0-3E14-467D-84B5-D17EE03414D6Q59049605-0F9F2D21-2771-41C0-8141-FFE839B141C5Q90104292-86DE786D-5BFC-403F-9748-A370AF3548C3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Victor Virlogeux
@ast
Victor Virlogeux
@en
Victor Virlogeux
@es
Victor Virlogeux
@nl
type
label
Victor Virlogeux
@ast
Victor Virlogeux
@en
Victor Virlogeux
@es
Victor Virlogeux
@nl
prefLabel
Victor Virlogeux
@ast
Victor Virlogeux
@en
Victor Virlogeux
@es
Victor Virlogeux
@nl
P106
P21
P31
P496
0000-0002-6282-0755